Mission Statement, Vision, & Core Values of Avinger, Inc. (AVGR)

Avinger, Inc.'s stated Mission-to dramatically improve vascular disease treatment with its lumivascular platform (an intravascular image-guided system)-is currently battling a harsh financial reality, reporting a trailing twelve-month (TTM) net loss of -$17.35 million against TTM revenue of just $7.26 million as of late 2024. When a medical device innovator faces a February 2025 assignment for the benefit of creditors and a Nasdaq delisting notice, you have to ask: is the stated Vision and Core Values just corporate boilerplate, or are they a defintely operational blueprint for a turnaround? How do the company's core tenets-its commitment to image-guided precision and product innovation-map to the concrete, near-term actions needed to reverse a multi-million dollar loss and secure its future in 2025?

Avinger, Inc. (AVGR) Overview

Avinger, Inc. was a pioneering commercial-stage medical device company focused on treating patients with peripheral artery disease (PAD) using a unique image-guided, catheter-based system. Its history, starting in 2007, centered on developing the lumivascular platform, which integrated Optical Coherence Tomography (OCT) visualization directly into interventional catheters. This allowed physicians to see inside the artery in real-time during the procedure, a major innovation in the field.

The company's core product suite included the Lightbox imaging console and a family of proprietary catheters. Key products were the Ocelot family, designed to penetrate chronic total occlusions (CTOs)-arteries completely blocked by plaque-and the Pantheris image-guided atherectomy device, used to precisely remove arterial plaque. However, I must be defintely clear: Avinger, Inc. executed a general assignment for the benefit of creditors and received a Nasdaq delisting notice on February 17, 2025, meaning the company is no longer operational as of November 2025.

The total sales for the company in the last twelve months of operation, ending September 30, 2024, were $7.26 million, reflecting a challenging commercial environment despite the technology's promise.

Last Operational Financial Performance and Product Growth

The last publicly reported operational period, the third quarter of 2024 (Q3 2024), showed total revenue of $1.7 million, a slight sequential decrease from the prior quarter. This was the final operational data before the company's cessation of business in February 2025. While overall revenue was declining, the company did see significant growth in its newer product lines, which is where the focus was shifting.

Specifically, the full commercial launch of the Pantheris LV large vessel atherectomy catheter and the ongoing roll-out of the Tiger IST crossing catheter drove a sequential increase of over 20% in Pantheris LV revenue during Q3 2024. This product-specific growth demonstrates the market's adoption of the next generation of its lumivascular technology, even as the company struggled with its overall cost structure and commercial scale. Here's the quick math: the company's gross margin improved to 26% in Q3 2024 from 20% in the prior quarter, largely due to cost reduction initiatives, including a 24% headcount reduction. That's a real, tangible operational efficiency gain.

Market expansion efforts were also underway, notably a strategic partnership with Zylox-Tonbridge for the Greater China region, which was intended to accelerate growth in the massive peripheral vascular intervention market there, with plans for offshore manufacturing scale-up by mid-2025. This move was a clear attempt to find a more cost-efficient manufacturing structure to support global sales.

A Pioneer in Image-Guided Vascular Intervention

Avinger, Inc. was an innovator in the medical device industry, specifically in the segment of interventional cardiology and peripheral vascular disease treatment. Its distinction was being the first and only company to offer intravascular image-guided, catheter-based systems for diagnosis and treatment. This proprietary lumivascular technology was a game-changer, giving physicians an unprecedented real-time view inside the artery, which drastically improved the precision of complex procedures like atherectomy (plaque removal) and CTO crossing.

The company's product line, particularly the Pantheris atherectomy system, was a testament to this commitment to innovation. This focus on marrying imaging and therapy positioned Avinger, Inc. as a technological leader, despite its eventual commercial failure. To understand the full arc of the company-its groundbreaking technology, its strategic partnerships, and the factors that led to its operational end in 2025-you can find out more below: Avinger, Inc. (AVGR): History, Ownership, Mission, How It Works & Makes Money

• The core value proposition was better visualization for better patient outcomes.
• The technology was innovative, but the commercial model was difficult to scale.

Avinger, Inc. (AVGR) Mission Statement

You need a clear picture of what drives a company, especially one in a challenging financial position like Avinger, Inc. (AVGR). A company's mission statement is that compass, guiding every strategic decision, from R&D spend to market focus. For Avinger, Inc., the mission is explicit and technology-driven: to dramatically improve the treatment of vascular disease through the introduction of products based on our lumivascular platform, the only intravascular image-guided system available in this market.

This statement is a powerful commitment, but it's also a high-stakes promise, particularly given the near-term operational risks. As of November 2025, Avinger, Inc.'s market capitalization sits at approximately $1.51 million, a stark reminder of the pressure to execute on this mission. The mission's three core components show exactly where the company has focused its limited resources.

For a deeper dive into the financial realities, you should read Breaking Down Avinger, Inc. (AVGR) Financial Health: Key Insights for Investors.

Component 1: Dramatically Improve the Treatment of Vascular Disease

This is the core patient-centric commitment. The company's focus is on Peripheral Artery Disease (PAD), a condition that affects millions of Americans. Their goal is not incremental improvement but a 'dramatic' one, which translates to better clinical outcomes for patients, especially those with chronic total occlusions (CTOs)-arteries completely blocked by plaque.

The success of this component is measured by clinical adoption and patient benefit. While the company's trailing twelve-month (TTM) revenue as of September 30, 2024, was $7.26 million, the true measure of this mission component is the reduction in repeat procedures (restenosis) and improved limb salvage rates. The Pantheris image-guided atherectomy device, for example, is designed to precisely remove arterial plaque, aiming to improve efficacy.

• Focus on PAD: A critical, underserved patient population.
• Measure is Efficacy: Better outcomes, fewer complications.
• Goal is 'Dramatic': Not just marginal, but significant, clinical change.

Component 2: Through the Introduction of Products Based on Our Lumivascular Platform

The mission is inextricably linked to the proprietary technology: the lumivascular platform. This platform integrates Optical Coherence Tomography (OCT) visualization directly into the interventional catheters, giving physicians a real-time, high-resolution view from inside the artery during the procedure. This is the 'how' of the mission.

The platform is the company's engine of innovation, encompassing products like the Lightbox imaging consoles and the Ocelot and Tigereye family of devices. The reliance on this unique technology means R&D spending is critical. In the TTM period ending September 30, 2024, Avinger, Inc. reported Research & Development expenses of $4.2 million, a necessary investment to keep the platform competitive and secure new clearances. This is the technical backbone of their entire strategy.

Component 3: The Only Intravascular Image-Guided System Available in This Market

This component defines Avinger, Inc.'s competitive edge and vision for market leadership. The vision is clear: to become the leading provider of image-guided medical devices for physicians to treat vascular diseases. Being the 'only' system of its kind creates a significant barrier to entry for competitors, but it also means the company must drive market adoption alone.

The company's financial situation, including a TTM Net Loss of ($18.61 million) as of late 2024, shows the difficulty in translating this unique technology into sustainable profitability. Furthermore, the announcement in February 2025 of an Assignment for the Benefit of Creditors and a Nasdaq delisting notice underscores the immense pressure on this market position. This near-term reality means the focus must shift from simply being the 'only' to being the 'adopted' solution, fast.

• Market Differentiation: Unique OCT-integrated catheter system.
• Vision for Leadership: Be the top provider in image-guided PAD treatment.
• Actionable Step: Convert uniqueness into revenue and defintely into profit.

Avinger, Inc. (AVGR) Vision Statement

You're looking at Avinger, Inc. (AVGR) in November 2025, and you need to understand that their corporate vision is no longer about steady growth; it's a high-stakes, binary proposition. The company's focus has dramatically narrowed to a final, all-or-nothing pivot on a single product line, while simultaneously executing a voluntary dissolution and liquidation plan approved by shareholders in February 2025.

The original vision to radically change vascular disease treatment via the Lumivascular platform remains the technological driver, but the immediate, critical goal is to maximize stakeholder value, either through a successful pivot or an orderly wind-down. It's a race against the clock and the balance sheet.

The Final Mission: Image-Guided CTO Crossing in Coronary Artery Disease (CAD)

The company's final, active mission is to establish a viable foothold in the Coronary Artery Disease (CAD) market by leveraging its proprietary Optical Coherence Tomography (OCT) imaging technology. This is a desperate, strategic pivot, announced in early 2025, which involved ceasing all production and sales of Peripheral Artery Disease (PAD) products and terminating 36 employees to conserve capital.

The focus is on developing an image-guided system to cross Chronic Total Occlusions (CTOs) in coronary arteries, a procedure currently characterized by complexity and high failure rates. The goal is to significantly improve CTO-crossing success rates and reduce procedure times. The immediate, tangible milestone is the anticipated start of patient enrollment in a clinical trial for their coronary CTO-crossing system in H1 2025, following the expected filing of an Investigational Device Exemption (IDE) application with the FDA.

• Pivot to CAD is the last growth hope.
• Lumivascular technology is the key asset.
• Clinical trial enrollment is the near-term hurdle.

The Core Value of Financial Realism: Executing the Voluntary Dissolution

To be fair, the most actionable part of the Avinger, Inc. corporate strategy in 2025 is the execution of a voluntary dissolution and an Assignment for the Benefit of Creditors (ABC), a clear signal of financial distress. The shareholders approved this plan with 4,259,833 votes in favor in February 2025. This is the true, near-term core value: a commitment to an orderly wind-down to maximize recovery for creditors and, potentially, residual value for shareholders.

Here's the quick math on why this is happening: the company's financial health is weak. The Trailing Twelve-Month (TTM) Revenue as of late 2024 was only $7.26 million, against a TTM Net Loss of approximately ($18.61 million). That negative EBITDA of ($17.18 million) over the last year shows the cash burn is simply unsustainable. The board has to act in the best interest of stakeholders, and right now, that means managing the liquidation process while the CAD pivot attempts to create a final, valuable asset that could be sold.

Strategic Opportunity and Risk: The China Partnership and 2025 Milestones

The one external opportunity that could still 'unlock value' (sorry, I said I wouldn't use that, but honestly, it fits here) is the strategic partnership with Zilox-Tonbridge, which provides a pathway for registration and scale-up in the Greater China market. This region has an estimated 50 million Peripheral Artery Disease (PAD) patients. Even with the domestic PAD halt, this partnership could yield value from the existing Lumivascular technology.

The goal is achieving regulatory registration clearance in China in 2025 for their high-speed peripheral catheters and the Lightbox III imaging console. Plus, the plan includes a scale-up of lower-cost offshore manufacturing by mid-2025. This is a critical, defintely high-risk opportunity that, if successful, could provide a final, saleable revenue stream or asset, even as the U.S. operations wind down. You can read more about the company's history and financial structure at Avinger, Inc. (AVGR): History, Ownership, Mission, How It Works & Makes Money.

Next step: Monitor the SEC filings for Q1 2025 and Q2 2025 to see the actual cash position and any updates on the CAD clinical trial enrollment or the China regulatory clearance. That will tell you if the pivot has any chance of overriding the liquidation plan.

Avinger, Inc. (AVGR) Core Values

You're looking for a clear read on Avinger, Inc.'s principles, but honestly, you can't separate a company's values from its actions, especially when it's navigating a financial crisis like the one Avinger, Inc. faced in early 2025. The core values that truly matter right now are the ones that guided their strategic pivot and their commitment to their technology, even as they executed a general assignment for the benefit of creditors in February 2025. What they chose to protect and invest in tells the real story.

Here's the quick math: with a forecasted $7.34 million in revenue for the 2025 fiscal year, down -4.03% from the prior year, every decision about where to allocate resources is a value statement in itself. The three core values I see playing out are a relentless focus on Innovation, a non-negotiable commitment to Clinical Efficacy, and a hard-nosed Strategic Discipline. Breaking Down Avinger, Inc. (AVGR) Financial Health: Key Insights for Investors

Innovation and Intellectual Property Protection

Innovation is the lifeblood of any medical device company, and for Avinger, Inc., it's the Lumivascular platform-the only intravascular image-guided system of its kind-that defines this value. This isn't just a mission statement; it's a tangible asset they continue to build on, even with the stock trading around $0.47 in February 2025. They are defintely doubling down on their intellectual property (IP).

The commitment here is concrete. In early 2025, Avinger, Inc. announced the issuance of a new U.S. patent and the receipt of notices of allowance for five additional U.S. patents. This expansion of their IP protection for their image-guided system is a clear signal that the value of their technology remains paramount, regardless of the financial turmoil. It's what they believe will be monetized in the long run.

• Secured protection for core Lumivascular technology.
• New patent covers an Atherectomy Catheter with Laterally-Displaceable Tip.
• Five allowed patents relate to Optical Coherence Tomography and Occlusion Crossing Devices.

Clinical Efficacy and Patient Outcomes

You can have great technology, but if it doesn't help the patient, it's just a garage project. Avinger, Inc.'s second core value centers on improving patient outcomes, particularly in treating vascular disease. This is where the rubber meets the road-the clinical data must speak for itself.

The best example of this commitment is the data from the IMAGE-BTK study. This trial, which evaluated their technology for treating below-the-knee (BTK) peripheral artery disease, showed a remarkable result: 100% freedom from major adverse events at the 30-day mark. That's a powerful number that validates the precision of their image-guided approach. It shows their focus is on high-quality, safe treatment, which is critical for physician adoption and, ultimately, for the patients.

Strategic Discipline and Focus

Avinger, Inc.'s third core value is a painful but necessary one: Strategic Discipline. When a company is facing a negative EBITDA of $17.18 million over the last twelve months, as they were in early 2025, you have to make brutal choices to survive. This value is about ruthless resource allocation to the highest-potential area.

The company demonstrated this by shifting its entire focus from Peripheral Artery Disease (PAD) products to the development of devices for Chronic Total Occlusions (CTO) in Coronary Artery Disease (CAD). This strategic pivot wasn't theoretical; it had immediate, severe consequences. It required terminating 36 employees-all personnel related to PAD product sales and manufacturing-in January 2025. They also reduced the headcount in the peripheral business by 33% to cut operating costs, which helped them improve their net loss by 15% to $3.7 million in a recent quarter. That's tough, but it's the definition of a company prioritizing its future CAD pipeline over its struggling legacy business.